futibatinib, Lytgobi, NCT02052778, Taiho Oncology, TAS-120-101

Cccelerated approval is granted by FDA to futibatinib for cholangiocarcinoma

November 2022: The Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic chol..

Ivosidenib has been approved by the FDA for advanced or metastatic cholangiocarcinoma

Sept 19, 2021: The Food and Drug Administration approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogen..

CBGJ398X2204, FGFR2 fusion, Infigratinib, kinase inhibitor, NCT02150967, QED Therapeutics, Truseltiq

Infigratinib receives accelerated approval from the FDA for metastatic cholangiocarcinoma

August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration for adults with previously treated, unresectable locally advanced or meta..